All In Biotech

NDA 209299 · Rigel Pharms

Tavalisse

Fostamatinib Disodium · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Apr 17, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

10 Phase 3, 0 recruiting

FAERS reports

7,889

2,613 serious, 493 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2025.

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Mechanism: Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2018 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
  • TAVALISSE · FOSTAMATINIB DISODIUM EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
  • TAVALISSE · FOSTAMATINIB DISODIUM EQ 150MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fostamatinib Disodium" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,068
  • product dose omission issue1,026
  • platelet count decreased1,019
  • off label use873
  • hospitalisation508
  • platelet count498
  • drug ineffective433
  • fatigue403
  • blood pressure increased384
  • death342
  • product prescribing issue316
  • headache273

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20171
2018155
2019619
2020650
2021454
2022773
20231,119
20241,302
20251,325
20261,490

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tavalisse (Fostamatinib Disodium)

2024 spending

$47.4M

Beneficiaries

562

3,395 claims

Per beneficiary

$84,373

$240.10 per unit

View as table
YearSpending
2020$21,711,458
2021$25,300,768
2022$32,398,967
2023$39,505,314
2024$47,417,690

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Rigel Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.